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Aims The REGENERATE-DCM trial is the first phase II randomized, placebo-controlled trial aiming to assess if granulocyte
colony-stimulating factor (G-CSF) administration with or without adjunctive intracoronary (IC) delivery of autologous
bone marrow-derived cells (BMCs) improves global left ventricular (LV) function in patients with dilated cardiomyop-
athy (DCM) and significant cardiac dysfunction.
Methods
and results
Sixty patients with DCM and left ventricular ejection fraction (LVEF) at referral of ≤45%, New York Heart Association
(NYHA) classification ≥2 and no secondary cause for the cardiomyopathy were randomized equally into four groups:
peripheral placebo (saline), peripheral G-CSF, peripheral G-CSF and IC serum, and peripheral G-CSF and IC BMC. All
patients, except the peripheral placebo group, received 5 days of G-CSF. In the IC groups, this was followed by bone
marrow harvest and IC infusion of cells or serum on Day 6. The primary endpoint was LVEF change from baseline to
3 months, determined by advanced cardiac imaging. At 3 months, peripheral G-CSF combined with IC BMC therapy
was associated with a 5.37% point increase in LVEF (38.30%+ 12.97 from 32.93%+ 16.46 P ¼ 0.0138), which was
maintained to 1 year. This was associated with a decrease in NYHA classification, reduced NT-pro BNP, and improved
exercise capacity and quality of life. No significant change in LVEF was seen in the remaining treatment groups.
Conclusion This is the first randomized, placebo-controlled trial with a novel combination of G-CSF and IC cell therapy that
demonstrates an improvement in cardiac function, symptoms, and biochemical parameters in patients with DCM.
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Introduction
Non-ischaemic dilated cardiomyopathy (DCM) is a leading cause of
heart failure and the most common indication for transplantation
worldwide.1,2 The prevalence of DCM is estimated at 1 in 2500
and although a proportion of patients recover cardiac function,
the majority suffer a progressive decline in left ventricular ejection
fraction (LVEF)3 with high levels of morbidity and mortality despite
optimal medical care.4
Novel approaches to promote recovery of myocardial function in
DCM have included cytokine and cell therapies. Clinical investiga-
tion of cytokine therapy alone has been limited and has failed to de-
liver long-lasting improvements in cardiac function.5 Autologous
bone marrow-derived cell (BMC) therapy has moved rapidly from
proof of concept in preclinical experiments to clinical trials of car-
diac repair in the most part in patients with acute myocardial infarc-
tion or heart failure secondary to ischaemic heart disease. Although
these early Phase I/II clinical trials have demonstrated mixed results,
meta-analysis has suggested that autologous cell therapy with or
without adjunctive cytokine has therapeutic potential in these pa-
tient groups.6 However, improvements in the intermediate out-
come measures used in these trials has been modest, suggesting
that adjunctive or alternative types of cell therapy may be needed
to achieve clinically meaningful results.
Patients with DCM are a small proportion of those entered into
these early stage trials. Two recent meta-analyses of autologous cell
therapy in patients with DCM have shown beneficial effects on
intermediate outcomes of disease such as cardiac function.7,8 To
date, there are few trials in DCM that combine cytokine and pro-
genitor cell injection none of which are blinded or fully controlled.9
Here we report the results of the first, randomized, blinded (within
arm), placebo-controlled trial combining autologous cell therapy
with adjunctive cytokine—granulocyte colony-stimulating factor
(G-CSF)—in the treatment of patients with DCM. We hypothe-
sized that intracoronary (IC) autologous BMC administration would
augment the pleotropic effects of G-CSF on cardiac function leading
to an increase in LVEF at 3 months compared with baseline accom-
panied by improvement in symptoms and biochemical markers of
heart failure.
Methods
Study design and participants
The study is a randomized, single centre, placebo-controlled Phase II
trial to determine if the administration of G-CSF alone or with adjunct-
ive IC autologous BMC in patients with DCM leads to an improvement
in LVEF. The trial was approved by an independent ethics committee,
the Medicines and Healthcare Products Regulatory Agency, registered
at approved registries (ClinicalTrials.gov: NCT01302171, EudraCT:
2009-013112-12) and was performed in accordance with the Declar-
ation of Helsinki (1993) and the principles of the International Confer-
ence of Harmonization—Good Clinical Practice guidelines. The full
protocol is available as Supplementary material online, Appendix and is
summarized as follows.
Potential patients were assessed for recruitment after referral from
heart failure specialists at the London Chest Hospital, the Heart
Hospital London, and the Royal Brompton Hospital London. All trial
procedures were carried out at the London Chest Hospital. Inclusion
criteria were a diagnosis of non-ischaemic DCM with no secondary
cause found, an LVEF of ,45% (assessed by echocardiography at
referral), symptoms classed as New York Heart Association (NYHA)
2 or greater and on optimal medical treatment (established for at least
6 months). Secondary cardiomyopathy was defined as pathological
myocardial involvement associated with systemic disorders, e.g. endo-
crine and metabolic disorders, alcohol and drug toxicity, infiltrative
disorders, and neuromuscular diseases.
Randomization and masking
After consenting for the trial, patients were randomized using a dedi-
cated trial software system (IHD Clinical Bishops Stortford, Herts,
UK) in a 1 : 1 : 1 : 1 simple randomization to one of four groups. The
four groups included: the ‘peripheral placebo group’ who received per-
ipheral subcutaneous injected saline, the ‘peripheral G-CSF group’ who
received subcutaneous G-CSF (GranocyteTM, Chugai Pharmaceutical
UK Ltd, Mulliner House, London) (10 mg/kg/day) for 5 days, the
‘IC BMC group’ who underwent bone marrow harvest after 5 days of
G-CSF and received IC infusion of autologous BMC, and the ‘IC serum
group’ who also underwent bone marrow harvest after 5 days of G-CSF
but received IC infusion of serum only. Intracoronary injection was
standardized to deliver cells equally between the major epicardial ves-
sels via the stop flow method as previously described.10 It was not pos-
sible for the study to be blinded across all four groups due to the
invasive nature of the IC arm. However, participants and investigators
were blinded within the IC arm between the IC BMC group and IC ser-
um groups and in the peripheral arm between saline and G-CSF. Data
analysers were entirely masked to group assignment in both trial arms.
Endpoints and definitions
The primary endpoint was the change in global LVEF at 3 months com-
pared with baseline as assessed by advanced cardiac imaging. Secondary
imaging endpoints included change in LVEF at 1 year (compared with
baseline) and changes in LV volumes and myocardial mass from baseline
at 3 months and 1 year. Secondary endpoints also included change in
NT-proBNP levels, exercise capacity (VO2 peak) NYHA classification
and quality of life as assessed by European Quality of Life-5 Dimensions
(EQ5D), and Kansas City Cardiomyopathy Questionnaire (KCCQ) at
3 months and 1 year compared with baseline. Mortality and adverse
cardiovascular events (MACE) defined as all-cause death, myocardial
infarction, hospitalization for heart failure, or major arrhythmias were
assessed at 3 months and 1 year. The safety of the IC infusion was
assessed by measurement of creatine kinase (CK) and Troponin T con-
centrations at 12 h post infusion and procedural complications.
Advanced cardiac imaging
Cardiovascular magnetic resonance (CMR) or cardiac computed
tomography (CT) for those unable to undergo CMR were performed
at baseline and 3 months. Conformity of the imaging modality was as-
sessed separately to ensure reproducibility and sensitivity. The standard
error of measurement of MRI and CT was 1.93 and 2.3%, respectively.
Multi-phase cardiac datasets with full left ventricular coverage were ac-
quired using standard protocols.11,12 The scans were anonymized,
batched, and analysed (Circulation, Siemens for CT and CMRtools, Car-
diovascular Imaging Solutions, London, UK) in blinded fashion by two
experienced operators (for full details of CT- and CMR-imaging proto-
cols see Supplementary material online).
Pulmonary exercise testing
Patients underwent exercise testing using a modified Bruce treadmill
test performed by an independent team at Royal Brompton NHS Trust.
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Patients were monitored throughout with tests being terminated
by physiological markers (ST changes, arrhythmias, or chest pain) or
by patient request.
Statistical design and analysis
The study was powered to the primary endpoint of change in LVEF at
3 months within each treatment group as measured by advanced cardiac
imaging. The sample size was calculated to detect an improvement in
LVEF of 3.5% with a power of 90% and significance level of 5%, as de-
monstrated by a contemporary meta-analysis of previous cell therapy
Phase I/II trials.13 The standard deviation for the advanced imaging LV
measurements was estimated as 4%. This equated to 13 patients in
each group, with the addition of 2 patients per group to account for
loss, to total 15 per group.
Data were analysed using a modified intention-to-treat approach,
meaning that patients who did not reach the primary and secondary
endpoints were not included in all analyses. Baseline demographic and
clinical variables were summarized for each group of the study. Continu-
ous variables are presented as means+ SD and categorical variables are
presented as percentages. 95% confidence intervals (CIs) are given.
Within group comparisons were performed using the paired T test.
Post hoc analyses between-group comparisons of all four groups were
performed using a one-way analysis of variance and on this basis com-
parisons between individual groups, e.g. the between peripheral group
comparison and between IC group comparison, were established using
the Bonferroni correction method. Chi square test was used to make
between-group comparisons of changes in NYHA class. P-values are
two sided with a value of ,0.05 considered to indicate statistical signifi-
cance. All statistical analyses were performed using SPSS version 19
(IBM Corp. Armonk, NY, USA) and graphs produced using Graphpad
Prism version 5.0 (GraphPad Software, San Diego, CA, USA).
Role of the funding source
No role of sponsor/funders in design or conduct of study.
Results
Between 6 July 2010 and 24 April 2012, 258 patients were screened
from specialized heart failure clinics at the three referring centres.
Of these patients, 132 were excluded for the following reasons:
baseline NYHA classification ,2 (n ¼ 30), LVEF, 10% or .45%
Figure 1 Consort diagram. Flow chart of the study design summarizing flow of patients through the trial.
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(n ¼ 46) on referral centre echocardiogram, secondary cause of
DCM (n ¼ 15), atrial fibrillation without permanent pacing (n ¼
14), weight .140 kg (n ¼ 1), creatinine .200 mmol/L (n ¼ 3),
and other (n ¼ 16). Sixty-six patients declined participation.
Of the 60 patients who were enrolled, DCM aetiology included:
idiopathic (n ¼ 49), post-myocarditis (n ¼ 5), and familial disease
(n ¼ 6). Data are presented for the 60 patients who were rando-
mized one of four groups: peripheral G-CSF (n ¼ 15), peripheral
placebo (n ¼ 15), IC BMC (n ¼ 15), and IC serum (n ¼ 15)
(Figure 1). A total of 58 patients reached the 3-month primary
endpoint and 53 patients reached 1 year follow-up.
The mean age for the total population was 54.55+ 11.19 years,
and 70% were male. At baseline, all groups were similar with
regard to age, sex, LVEF, plasma NT-proBNP concentration, or
medical/ device management (Table 1). Changes in medications
were minimal during the 3-month study period as inclusion criteria
specified medical treatment had to be stabile for 6 months prior to
treatment.
Peripheral concentrations of CD34+ cells were significantly
greater in patients who had G-CSF therapy (see Supplementary ma-
terial online, Table S1). The average plasma CD34+ concentration
increased from 3.94+ 3.54/mL at baseline to 56.79+ 45.13/mL
after 6 days of G-CSF therapy; P ¼ ,0.0001. In the IC BMC group,
the total mononuclear cell count in the injected cell product was
216.0 × 106+ 221.8 with a mean percentage of viable cells of
98.2+ 1.0 (see Supplementary material online, Table S2). The
mean number of CD34+ cells in the cell product (as a measure
of stem-like potential of the BMC population) was 4.91 × 106+
2.75. The mean granulocyte-macrophage colony forming unit cap-
acity per 2 × 104 BMC (as a measure of functionality of the applied
cells) was 7.42+4.40.
Cells were injected into three coronary arteries in 10 patients and
into the left anterior descending and circumflex arteries only in 5 pa-
tients. No cases of distal coronary artery occlusion, acute cardiac
dysfunction, ventricular arrhythmia or significant CK or troponin
T release occurred. One patient suffered a localized coronary dis-
section during infusion and was treated with coronary stenting but
with no significant change in CK.
Left ventricular ejection fraction
Twenty-two patients underwent CMR assessment of cardiac func-
tion and 38 CT assessment (see Supplementary material online,
Table S3). Baseline measurements of LVEF did not differ significantly
between the treatment groups (Table 1). Primary endpoint anal-
ysis revealed that the IC BMC group showed a 5.37% point
increase (SD 7.39) in global LVEF from 32.93%+ 16.46 at baseline
to 38.30%+ 12.97 at 3 months (P ¼ 0.0138, n ¼ 15). No signifi-
cant change was seen in any of the other treatment groups be-
tween baseline and 3 months (peripheral G-CSF group mean
difference: 0.14%+ 8.05; P ¼ 0.9481, n ¼ 14; peripheral placebo
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Table 1 Baseline characteristics of the study population
Peripheral
placebo (n5 14)
Peripheral
G-CSF (n5 14)
Intracoronary serum
(n 5 15)
Intracoronary BMC
(n5 15)
P-value
Age (years), mean (SD) 56.79 (9.84) 54.57 (9.76) 54.87 (10.86) 57.67 (12.32) 0.4395
Sex (M/F) 12/2 10/4 9/6 10/5 0.4307
BMI (kg/m2), mean (SD) 29.15 (4.48) 29.19 (5.19) 28.26 (9.10) 27.23 (4.33) 0.7338
Hypertension, no. (%) 2 (14.2%) 1 (7.1%) 1 (6.6%) 2 (13.3%) 0.8728
Hypercholesterolaemia, no. (%) 3 (21.4%) 2 (14.2%) 1 (6.6%) 0 (0%) 0.3081
Diabetes mellitus, no. (%) 2 (14.2%) 1 (7.1%) 1 (6.6%) 2 (13.3%) 0.8728
Active smoker, no. (%) 2 (14.2%) 1 (7.1%) 2 (13.3%) 2 (13.3%) 0.9279
Family history of any heart disease, no. (%) 2 (14.2%) 1 (7.1%) 2 (13.3%) 2 (13.3%) 0.3576
Time from diagnosis to randomization
(year), mean (SD)
5.43 (0.98) 7.6 (2.09) 8.00 (1.61) 4.9 (0.96) 0.3132
Medical therapy
ACEi/ARB, no. (%) 13 (92.9%) 14 (100%) 15 (100%) 15 (100%) 0.3997
b-Blockers, no. (%) 14 (100%) 12(83.7%) 13 (86.6%) 13 (86.6%) 0.3963
Diuretics, no. (%) 8 (57.1%) 8 (57.1%) 8 (53.3%) 9 (59.9%) 0.7349
Aldosterone antagonists, no. (%) 11 (78,6%) 7 (50.0%) 12 (79.9%) 10 (66.6%) 0.3356
Digoxin, no. (%) 2(14.2%) 5 (35.7%) 4 (26.6%) 6 (39.9%) 0.4282
LVEF
Baseline, mean (SD) 29.75 (9.191) 36.5 (13.26) 41.70 (15.25) 32.93 (16.46) 0.1289
Device therapy
ICD, no. (%) 3 (21.4%) 5 (35.7%) 4 (26.6%) 4 (26.6%) 0.8859
Biventricular pacemaker, no. (%) 1 (7.1%) 0 (0%) 2 (13.3%) 2 (13.3%) 0.5113
CRT-D, no. (%) 6 (42.9%) 4 (28.6%) 3 (19.9%) 7 (46.6%) 0.4077
BMI, body mass index; G-CSF, granulocyte colony-stimulating factor; ACE, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ICD, implantable
cardioverter defibrillator; CRT-D, cardiac resynchronization therapy defibrillator; LVEF, left ventricular ejection fraction.
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group mean difference: 21.07%+8.11; P ¼ 0.6294, n ¼ 14; serum
group mean difference: 21.1+5.65; P ¼ 0.4634, n ¼ 15) (Figure 2i).
Between-group analyses demonstrated the change in LVEF at 3
months was significantly greater in the IC BMC group compared
with the IC serum group (absolute change in LVEF of 6.47%; P ¼
0.0119), and peripheral placebo group (absolute change in LVEF
of 6.44%; P ¼ 0.0430). The between IC BMC group and peripheral
G-CSF group difference did not reach significance (absolute change
in LVEF of 5.22%).
At 1 year the improvement in cardiac function was maintained in
the IC BMC group with a 7.04% point increase (SD 7.77) in LVEF
from baseline (42.92%+ 12.20 from 35.88%+ 15.45; P ¼ 0.0067,
n ¼ 13). Again, at 1 year, the change in LVEF was significantly greater
in the IC BMC group compared with all other treatment groups
(P ¼ 0.0109): IC serum group (P ¼ 0.0420), peripheral placebo
group (P ¼ 0.0141), and peripheral G-CSF group (P ¼ 0.0058).
There was no significant difference in improvement of LVEF in pa-
tients who received BMC infusion in 3 or 2 coronary arteries. In
the patients who showed improvement in LVEF at 1 year, there
was a suggestion of an association between number of BMC injected
and improvement in LVEF (r2 ¼ 0.4848, P ¼ 0.037, Supplementary
material online, Figure S1).
No evidence of a difference was seen in LV end systolic volume
(LVESV), LV end diastolic volume (LVEDV), stroke volume (SV),
or myocardial mass (MM) over time in any of the treatment groups
(see Supplementary material online, Table S3).
Figure 2 Endpoint analysis of left ventricular ejection fraction, NT-proBNP, and VO2 max. Box and whisker plots (median and range, mean
shown by +) including individual datapoints of primary and secondary endpoints of the REGENERATE-DCM trial measured at 3 months and
1 year. Endpoints: (i) left ventricular ejection fraction, (ii) NT-proBNP, (iii) VO2 max patient groups (A) peripheral placebo, (B) peripheral gran-
ulocyte colony-stimulating factor, (C) intracoronary serum infusion, and (D) intracoronary bone marrow-derived cell infusion.
The REGENERATE-DCM clinical trial 3065
Plasma NT-proBNP concentration
NT-proBNP analysis was performed at baseline, 3 months and 1 year;
results underwent logarithmic transformation due to non-normal dis-
tribution. There was significant decrease in NT-proBNP in the IC
BMC group at 1 year (2136.0 pg/mL; 95% CI, 2519.6–247.6; P ¼
0.0023) which was significantly greater than the change seen in the
IC serum group (diff: 171.5 pg/mL; 95% CI, 2200.6–543.6; P ¼
0.0420) (Figure 2ii; Supplementary material online, Table S4).
Exercise capacity
Fifty-six patients underwent pulmonary exercise testing at baseline
and 3 months with 49 undergoing further assessment at 1 year. At 1
year, there was a significant improvement in VO2 peak in the IC
BMC group (17.67+ 5.76–21.23+ 6.23 ml/kg/min; P ¼ 0.0179)
(Figure 2iii).
The IC BMC group showed a significant improvement in maximum
exercise speed at 3 months (1.95+ 0.71–2.55+ 1.06 mph; P ¼
0.0192) and 1 year (1.95+0.71–3.27+1.06 mph; P¼ 0.0164) asso-
ciated with an increase in exercise time at both time points (424.1+
183.2 s–504.0+239.0 s; P ¼ 0.0146 and 415.8+183.7 s–578.1+
272.8 s, P¼ 0.0131 respectively) (see Supplementary material online,
Table S5).
NYHA
The percentage of patients who showed improvement in their
NYHA classification was significantly higher in the IC BMC group
(x2 ¼ 14.92, diff ¼ 6; P ¼ 0.02). In the IC BMC group with six
(40%) patients showed improvement in NYHA class with no pa-
tients demonstrating a deterioration. In the IC serum group only
one (6.7%) patient showed improvement, in the peripheral G-CSF
Figure 2 Continued
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group three (20%) patients showed improvement, and in the
peripheral placebo group no patients showed improvement. At 1
year, this pattern continued with eight (66.7%) patients improving
in the IC BMC group, three (23.0%) patients improving in the IC
serum group, three (21.4%) patients improving in the peripheral
G-CSF group, and one (8.3%) patients improving in the peripheral
placebo group (x2 ¼ 12.61, diff ¼ 6; P ¼ 0.0497) (Figure 3).
Quality of life
Using the EQ5D index score and EQ5D visual analogue scale, there
was no improvement in quality of life at 3 months in any of the treat-
ment groups. At 1 year, the EQ5D index score showed evidence of
improvement in quality of life in the peripheral G-CSF group only
(0.462+ 0.350–0.647+ 0.236; P ¼ 0.013) (see Supplementary
material online, Table S6).
Using the KCCQ clinical summary score, there improvement in
the patient’s symptoms and social factors in the IC BMC group 3
months (54.64+ 21.80–64.34+ 25.83; P ¼ 0.0028) and 1 year
(63.67+ 27.62; P ¼ 0.0005 compared with baseline). The KCCQ
overall summary score also showed an improvement at 1 year in
both the IC BMC group (38.66+ 20.96–56.27+ 29.96; P ¼
0.0053 and the peripheral G-CSF group (50.80+ 21.27–60.26+
21.16; P ¼ 0.0438 (see Supplementary material online, Table S6).
Safety
There were no complications or adverse events associated with
G-CSF therapy. Seven patients (15.6%) reported the common
side effect of long bone pain during therapy. There was one report
of MACE in each of the peripheral groups at 1 year, two reports
of MACE in the IC BMC group and three reports of MACE in
Figure 2 Continued
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the IC serum group at 1 year. There were two deaths in the IC BMC
group at 1 year due to causes unrelated to the trial: non-cardiac sur-
gical procedure complication and bronchopneumonia (see Supple-
mentary material online, Table S7).
Discussion
This is the first placebo-controlled trial of patients with DCM asses-
sing the combination of cell and cytokine therapy to demonstrate a
significant increase in cardiac function supported by improvements
in symptoms, exercise physiology, and biochemical markers of heart
failure. Granulocyte colony-stimulating factor alone did not have a
beneficial effect on cardiac function supportive of recent meta-
analysis data.14 The G-CSF/IC BMC patients demonstrated a
5.37% increase in LVEF at 3 months, which was maintained at
1 year. This LVEF improvement was associated with significant im-
provements in the clinical parameters of NYHA class, exercise
capacity, quality of life decrease in NT-pro BNP at 1 year. The re-
maining treatment groups failed to show evidence of improvement
in any of these endpoints at either 3 months or 1 year. These results
therefore demonstrate the beneficial effects across multiple clinical
and intermediate parameters of combined cell and cytokine therapy
in a randomized control trial of patients diagnosed with DCM. Since
the trial was designed to test whether BMC in addition to G-CSF
provided added benefits it is not clear whether cell therapy alone
would have had a similar effect.
Similar beneficial effects on cardiac function with BMC therapy
have been shown in other early phase studies,15,16 with the most re-
cent demonstrating improvements out to 5 years post therapy.9
However, no study has been performed with a randomized interven-
tional control group blinded to the investigators. Previous studies
have also used G-CSF alone but few have controlled for the possibility
that this cytokine may have a direct effect on cardiac function as has
been previously suggested.17 REGENERATE-DCM is the first trial de-
signed with a separate interventional and cytokine only control group.
Although the peripheral G-CSF group did not show an improvement
in intermediate and clinical endpoints, there was an improvement in
quality-of-life scores highlighting the need for rigorous study design
involving appropriate control arms as previously suggested.7
The results presented here also support the hypothesis that the
additional beneficial effects of IC BMC in combination with G-CSF
compared with G-CSF alone are in part mediated by the local deliv-
ery of an enriched CD34+ cell population. Here CD34+ concen-
trations in the infused cell product are shown to be an order of
magnitude above circulating CD34+ concentrations achieved by
mobilization with G-CSF alone (491 CD34+/mL in cell product
compared with 56.8 CD34+/mL in the circulation Supplementary
material online, Tables S1 and S2).
The enrolled study population was typical of a DCM population
with similar baseline characteristics and medical therapy to patients
in other published trials.18,19 The biochemical markers indicating
severity of heart failure were similar across all groups with a plasma
NT-proBNP concentration .1000 pg/mL suggestive of significant
left ventricular dysfunction. The patient population had high levels
of optimal medical therapy and appropriate levels of ‘device therapy’
in all groups in keeping with current European guidelines.20
While patients were enrolled to the trial and randomized on the
basis of referring echo criteria of LVEF ,45%, their baseline LVEF
measurements by MRI and CT were in some instances.45%, which
is a recognized limitation of the study. Furthermore, although the
baseline LVEF in the IC serum arm was increased compared with
the other three groups, there was no significant between-group dif-
ference. It must also be noted here that although rate of MACE was
not different between the treatment groups two deaths occurred
within the IC BMC group which were unrelated to trial procedures
and non-cardiac in aetiology. Although it is unusual that both events
occurred within one group, a mortality rate of 2/60 may be reason-
able in such a high-risk study population.
The results of the REGENERATE-DCM trial suggest a beneficial
effect of combination G-CSF and BMC therapy; however, this is a
Phase II trial powered around intermediate efficacy measures. The
trial met its statistical endpoint criteria despite the small sample
size, which was supported by relevant changes in the secondary
endpoints. It is likely that small study size accounted for a failure
to see significant changes in LVESV and LVEDV, that corresponded
to improvement of LVEF, observations that have been linked in large
meta-analyses.21 ***LVESV and LVEDV have a combined effect on
LVEF therefore increasing sample size may have revealed significant
Figure 3 Change in NYHA. Bar chart showing symptomatic change as measured by change in NYHA classification per treatment group at
3 months and 1 year. Percentages reflect number of patients that have worsened, improved, or remain unchanged compared with baseline.
(Note: unchanged is not represented by area). *Significance at P, 0.05.
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changes. The study could not be completely blinded across all arms
due to the invasive nature of the IC arm. Nonetheless, the investiga-
tors and patients were blinded within arm between active treatment
and placebo and data analysers were blinded to all treatment
groups. Although patients underwent either MRI or CT analysis
since the scans were paired and the primary endpoint was based
on within group measures any modality-related differences in the
measurements of cardiac function would not account for the signifi-
cant findings. Furthermore, the standard error of measurement of
MRI and CT was similar.
Therefore, results of REGENERATE-DCM demonstrate im-
provement in a panel of measures of cardiac function accompanied
by improvement in symptoms. In particular the change in plasma
NT-proBNP at 1 year suggest that cell therapy may lead to a long-
term outcome benefit in these patients and therefore warrants
further investigation using the methodology described in this manu-
script in a Phase III trial.
Conclusion
The IC infusion of autologous unfractionated BMC in combination
with G-CSF therapy in patients with DCM appears to be safe and is
associated with an improvement in LVEF 3 months after therapy,
which is maintained at 1 year. These functional differences were ac-
companied by improvement in a panel of biochemical and symptom-
related outcomes supporting a potential clinical benefit of this therapy.
Supplementary material
Supplementary material is available at European Heart Journal online.
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